- Home
- MDB vs ONC Comparison
MDB vs ONC Comparison
Compare MDB & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDB | ONC |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0B | 31.4B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | MDB | ONC |
|---|---|---|
| Price | $325.04 | $322.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 34 | 10 |
| Target Price | $368.67 | ★ $385.10 |
| AVG Volume (30 Days) | ★ 1.3M | 354.8K |
| Earning Date | 06-03-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.13 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.68 | $723.76 |
| Revenue Next Year | $17.10 | $15.04 |
| P/E Ratio | $6,422.00 | ★ $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $198.47 | $253.95 |
| 52 Week High | $444.72 | $385.22 |
Technical Indicators
Market Signals| Indicator | MDB | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 48.59 | 67.74 |
| Support Level | $298.08 | $325.47 |
| Resistance Level | $362.27 | $328.39 |
| Average True Range (ATR) | 19.70 | 8.03 |
| MACD | -2.09 | 1.40 |
| Stochastic Oscillator | 35.95 | 87.66 |
Price Performance
Historical ComparisonAbout MDB MongoDB Inc.
Founded in 2007, MongoDB is a vendor of a document-oriented database that accelerates development processes of new applications. Enterprise customers can choose between the fully managed offering, MongoDB Atlas, or the self-managed version, MongoDB Enterprise Advanced. MongoDB is a popular tool among developers, and its free Community Server has recorded over 500 million downloads since 2009.
About ONC BeiGene Ltd. American Depositary Shares
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.